GlaxoSmithKline has extended its $2.6 billion offer to buy long-time partner Human Genome Sciences until the end of June as it battles the US biotech company's reluctant management.
The price remains unchanged at $13 a share under the
The first new treatment for lupus in a half-century has won US approval, a milestone for patients with the disabling disease and a potential blockbuster for its tiny biotech maker.
Health officials cleared Benlysta, discovered by Human Gen
Human Genome Sciences Inc said on Monday that its experimental lupus drug had succeeded in a late-stage clinical trial, shocking many who had written the product off as dead and fueling a 228 per cent stock jump.
The results, which were an